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OBJECTIVES We sought to assess the effects of heparin and the potential protective effects of trimetazidine
(TMZ) on exercise performance, plasma nitric oxide (NO), endothelin-1 (ET-1) and free
fatty acid (FFA) release in patients with stable coronary artery disease (CAD).
BACKGROUND Heparin has been shown to reduce the ischemic threshold in patients with CAD.
Trimetazidine may affect myocardial substrate utilization by shifting energy production from
FFA to glucose oxidation.
METHODS In four consecutive days, nine patients with CAD each received one of the following four
regimens: 1) one tablet of placebo the evening before and at 8 AM and 4 PM on the day of the
study, 10 ml of saline in a bolus 10 min before exercise, followed by an infusion of the same
preparation; 2) placebo at the same times as in the first regimen, 5,000 IU of heparin 10 min
before exercise, followed by 1,000 IU/h; 3) 20 mg TMZ at the same times as in the first
regimen, 5,000 IU of heparin 10 min before exercise, followed by 1,000 IU/h; or 4) TMZ at
the same times as in the first regimen, 10 ml of saline 10 min before exercise, followed by an
infusion of the same preparation.
RESULTS During placebo (test 2), heparin reduced the time to 1-mm ST-segment depression and
prolonged the recovery time, as compared with the results of test 1. When heparin was
administered after TMZ (test 3), the time to 1-mm ST-segment depression and the recovery
time were similar to those recorded during saline (test 1). Finally, compared with all study
phases, TMZ during saline (test 4) prolonged the time to 1 mm. No changes in NO release
were found, whereas ET-1 was decreased at peak exercise and during recovery, when the
patients were receiving TMZ (tests 3 and 4). Free fatty acids increased after heparin, both
with placebo and TMZ.
CONCLUSIONS In patients with CAD, heparin reduces the ischemic threshold. Trimetazidine reduces the
effects of heparin, probably by inhibiting FFA oxidation and enhancing glucose metabolism.
The concomitant novel observation of reduced ET-1 release is likely to be also dependent on
TMZ-induced improvement of endothelial metabolism or reduction of myocardial
ischemia. (J Am Coll Cardiol 2002;39:413–9) © 2002 by the American College of
Cardiology
Heparin is universally employed as an antithrombotic agent
in patients with acute coronary syndromes. However, its
administration is known to increase circulating free fatty
acids (FFAs) (1), which may adversely affect myocardial
energetics, especially during ischemia (2). In addition,
although low-dose heparin infusion can increase nitric oxide
(NO) levels and forearm blood flow in normal subjects (3),
recent studies have shown that high-dose heparin, at con-
centrations often achieved in acute cardiovascular condi-
tions, increases platelet aggregation (4,5) and impairs NO
production and vasomotion in rats (6). These observations
suggest the possibility that heparin exerts a prothrombotic
effect and may imply, theoretically at least, that high-dose
heparin could also negatively affect myocardial perfusion by
interfering with the production of constitutive NO. Re-
cently, our group has shown that standard unfractionated
heparin may reduce the ischemic threshold in patients with
coronary artery disease (CAD), probably by increasing FFA
release (7). Although low-molecular-weight heparin has
been shown to yield a weaker plasma lipolytic potential
(8,9), unfractionated heparin, by mobilizing lipoprotein
lipase, which hydrolyzes serum triglycerides and increases
nonesterified fatty acid availability, may further worsen the
metabolic milieu of the ischemic myocardium. In fact,
exogenous fatty acids, the main metabolic fuel of the
myocardium under aerobic conditions, are detrimental un-
der oxygen deprivation, because their presence further
augments the accumulation of long-chain acyl esters in the
myocytes. The accumulation of lipids and their degradation
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may contribute to the progression of injury. However, if
glucose oxidation could be stimulated during ischemia-
reperfusion, this would result in a significant increase in
cardiac efficiency, as determined by a reduction of lactate
production and acidosis, and an increase in adenosine
triphosphate (ATP) content, with a parallel improvement in
cardiac function and lesser injury.
Trimetazidine, 1(2,3,4-trimethoxybenzyl-piperazine di-
hydrochloride; TMZ), has been reported to exert anti-
ischemic properties without affecting myocardial oxygen
consumption and blood supply (10). The beneficial effect of
this agent has been attributed to preservation of phospho-
creatine and ATP intracellular levels (11) and a reduction of
cell acidosis (12,13), calcium overload (13) and free radical–
induced injury caused by ischemia (14). More importantly,
TMZ affects myocardial substrate utilization by inhibiting
oxidative phosphorylation and by shifting energy production
from FFA to glucose oxidation (15,16). Recent evidence
indicates that this effect is predominantly caused by selective
blockade of long-chain 3-ketoacyl coenzyme A thiolase
activity, the last enzyme involved in beta-oxidation (16).
Several clinical studies have shown that TMZ alone or in
combination with other anti-anginal drugs can substantially
improve exercise tolerance and increase the ischemic thresh-
old in patients with effort angina (17–22).
The aims of the present study were to investigate, in
patients with chronic stable angina, the effects of short-term
heparin administration on the ischemic threshold, plasma
NO, endothelin-1 (ET-1) and FFA release and, in this
context, to evaluate the potential protective effect of TMZ.
METHODS
Patients. Nine consecutive patients (all males, age 63  6
years) with angiographically proven CAD awaiting percu-
taneous revascularization were selected for the study. All
had a reproducibly positive exercise test. Patients with a
previous myocardial infarction or any cardiac condition
potentially interfering with the unequivocal interpretation
of the 12-lead electrocardiogram (ECG) were excluded
from the study. Anti-ischemic medications and statins were
withdrawn at least 72 h before the beginning of the study.
All patients were taking salicylates, which were not with-
drawn for study purposes. None of the patients had overt
diabetes mellitus. Three had mild glucose intolerance,
controlled by diet only. All patients gave written, informed
consent to participate in the study.
Protocol. The study consisted of four randomized, double-
blinded phases conducted on consecutive days. In separate
sessions, patients underwent exercise testing under the
following medications, given in random order—test 1: one
tablet of matching placebo given the evening before and at
8 AM and 4 PM on the day of the study and a 10-ml bolus of
0.9% NaCl given 10 min before exercise testing (according
to the Bruce protocol, at 5 PM), followed by an infusion of
the same solution (12 ml/h) until the end of recovery; test 2:
one tablet of placebo the evening before, at 8 AM and 4 PM
and a 5,000-IU bolus of heparin given 10 min before
exercise, followed by an infusion of 1,000 IU/h; test 3: 20
mg TMZ given the evening before and at 8 AM and 4 PM
and a 5,000-IU bolus of heparin given 10 min before
exercise, followed by an infusion of 1,000 IU/h; and test 4:
20 mg TMZ given the evening before and at 8 AM and 4 PM
and a 10-ml bolus of 0.9% NaCl given 10 min before
exercise testing, followed by infusion of the same solution.
Treadmill exercise testing (CASE 12-Marquette Electron-
ics, Milwaukee, Wisconsin) was performed at 5 PM, in the
fasting state, according to the Bruce protocol. Blood pres-
sure (measured by a cuff sphygmomanometer) and the
12-lead ECG were recorded at baseline, after the heparin
and NaCl boluses, during the third minute of each exercise
step and throughout recovery. Exercise was terminated
when there appeared 2-mm rectilinear or downsloping
ST-segment depression or severe angina, fatigue, ventricular
tachycardia or a blood pressure decrease 10 mm Hg.
Heart rate, systolic and diastolic blood pressures and rate–
pressure product (RPP) were measured at rest, at the
appearance of 1-mm ST-segment depression and at peak
exercise. The time to 1-mm ST-segment depression and to
peak exercise and the recovery time (time to ST-segment
return to baseline during recovery after exercise) were
recorded. Achieved percent age-adjusted maximal predicted
heart rate (220  patient age), maximal ST-segment de-
pression, cumulative maximal ST-segment depression and
the number of ECG leads showing diagnostic changes were
also measured.
Biochemical testing. Blood sampling for NO, ET-1, lac-
tate and FFA determination was performed at 15 min, at
0 time, at peak exercise and after 10, 15 and 20 min from
the end of exercise. Levels of NO were evaluated by
measuring the end products of their metabolism (i.e., nitrite
and nitrate levels), using enzymatic catalysis coupled with
the Griess reaction. Specifically, NO3 was reduced to NO2
by 0.1 U nitrate reductase, 5  106 mol/l flavin adenine
dinucleotide and 250  106 NADPH. The samples were
incubated at 37°C for 3 h, then 8.8 U lactic dehydrogenase
and 102 mol/l pyruvate was added, and the samples were
incubated for an additional 90 min at 37°C. Finally, the
Griess reaction was added to each well, and the samples
were read at 540 nm (23).
Abbreviations and Acronyms
ANOVA  analysis of variance
ATP  adenosine triphosphate
CAD  coronary artery disease
ECG  electrocardiogram or electrocardiographic
ET-1  endothelin-1
FFA  free fatty acid
NO  nitric oxide
RIA  radioimmunoassay
RPP  rate–pressure product
TMZ  trimetazidine
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For measurement of ET-1, the samples were extracted on
a SepPack C18 mini-column (Amprep, Amersham Inter-
national, Buckingamshire, U.K.), and the eluate was evap-
orated in a Speed VAC SC 110 (Savant Instruments, Inc.,
Farmingdale, New York). The samples were reconstituted
with 250 l of radioimmunoassay (RIA) buffer and assayed
with an RIA kit (Du Pont de Nemours, Boston, Massachu-
setts). Typical intra- and inter-assay coefficients of variation
were 3.0% and 11.9%, respectively (24).
Levels of FFA and lactate were determined by the
spectrofluorometric enzymatic method, adapted to a Cobas
Fara Centrifugal Analyzer (Roche, Basel, Switzerland) (25).
Statistical analysis. Data are reported as the mean value 
SD. Comparisons among groups were performed by one-
way analysis of variance (ANOVA). When variables did not
show a gaussian distribution, nonparametric analysis was
undertaken to investigate the differences among groups.
Friedman’s test for paired samples was performed, and
Dunn’s multiple comparisons method was used for post hoc
comparisons. The FFA, ET-1, NO2/NO3 and lactate
results were analyzed by using two-way ANOVA with
repeated measures of one factor. When the time–group
interaction was significant, tests for simple effects were
performed (paired t test: time 0 vs. peak exercise in different
groups and one-way ANOVA among groups at different
times), and the Bonferroni adjustment for post hoc com-
parisons was performed. Pearson and Spearman correlation
coefficients were also calculated, where appropriate. Analysis
was performed with SAS 6.12 (SAS Institute Inc., Cary,
North Carolina).
RESULTS
Exercise testing. Table 1 shows detailed results pertaining
to the ergometric parameters. Compared with test 1, test 2
administration of heparin reduced the time to 1-mm ST-
segment depression (259  185 vs. 321  179 s, p  0.05)
and prolonged recovery time (704  164 vs. 518  263 s,
p  0.05) (Fig. 1), although it did not significantly increase
maximal ST-segment depression (Fig. 2).
When heparin was administered after TMZ (test 3), the
time to 1-mm ST-segment depression (318  174 s) and
the recovery time (472  186 s) were similar to those
recorded during saline administration (test 1) (Fig. 1). No
significant differences in basal and peak heart rate or systolic
and diastolic blood pressure were found. Accordingly, the
RPPs at 1-mm ST-segment depression and at peak exercise
were similar in all study phases (Fig. 3). Finally, compared
with all study phases, TMZ during saline (test 4) induced a
significant prolongation of the time to 1-mm ST-segment
depression.
Biochemical results. Figure 4 shows the profile of bio-
chemical results. No significant differences were found in
the plasma levels of FFA, ET-1 and NO2
/NO3
 and
lactate before the beginning of the tests. Plasma FFA levels
were different among tests (F  28.9, p  0.001); the main
effect of time was significant (F 75.7, p 0.001); and the
rate of increase was different among different tests (time–
test interaction: F  26.3, p  0.001). Plasma FFA
increased by 10-fold during tests 2 and 3 (heparin, with and
without TMZ, p  0.001), but only a slight increase was
observed during tests 1 and 4 (p  0.01).
The time effect was significant for ET-1 levels (F  7.5,
p  0.001). The main effect of the tests was not significant
(F  2.22, p  0.1). Moreover, there was a significant
interaction between the effect of changes in ET-1 levels and
different treatments (F  4.86, p  0.007). During the first
10 min of saline or heparin infusion, the ET-1 levels
remained unchanged in all patients. The paired t test, used
to investigate the difference between time 0 and peak time,
showed that at the end of the exercise period, ET-1 levels
increased in test 1 (from 7.6  0.6 to 9.9  0.9 pg/ml, p 
Table 1. Ergometric Parameters
MPHR
(%)
RPP at 1-mm
ST-Segment
Depression
RPP at
Peak Exercise
Time (s) to 1-mm
ST-Segment
Depression
Time (s)
to Peak
Exercise
Recovery
Time (s)
Maximal
ST-Segment
Depression (mm)
No. of
ECG Leads*
Placebo  NaCl 96  8 28,873  5,119 30,658  3,601 321  179 408  161 518  263 2.02  1.18 4.33  1.73
Placebo  Heparin 95  10 26,337  7,021 30,613  5,947 259  185† 409  174 704  164† 2.31  1.13 5.22  1.79
TMZ  Heparin 95  7 26,816  8,009 30,720  5,790 318  174 420  174 472  186 1.74  0.90 4.67  2.55
TMZ  NaCl 99  4 29,367  5,428 31,327  2,035 468  198‡ 558  99 493  80§ 1.70  1.04 4.33  1.52
*Number of electrocardiographic leads showing diagnostic ST-segment depression. Dunn’s multiple comparisons: †p  0.05 versus placebo  NaCl and TMZ  heparin;
‡p 0.05 versus placeboNaCl and placebo heparin and TMZ heparin; and §p 0.05 versus placebo heparin. Data are presented as the mean value SD of ergometric
parameters in the four phases of the study.
ECG  electrocardiographic; NaCl  sodium chloride; MPHR  maximal predicted heart rate; RPP  rate–pressure product; TMZ  trimetazidine.
Figure 1. Bar graphs pertaining to the time (seconds; mean  SD) to
1-mm ST-segment depression, to peak exercise and to the end of the
recovery period, during saline and heparin, with placebo and trimetazidine
(TMZ). Solid bar  saline and placebo; striped bar  heparin and
placebo; checkered bar  heparin and TMZ; open bar  saline and
TMZ. Refer to Table 1 for all significance levels, if not shown in figure.
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0.005) and increased further during test 2 (from 7.6  0.7
to 11.2  1.9 pg/ml, p  0.01). Conversely, during test 3,
ET-1 levels remained unchanged (from 7.7  0.7 to 8.1 
0.9 pg/ml, pNS) and decreased during test 4 (from 7.0
0.6 to 5.8  0.3, p  NS). Fifteen minutes after the end of
exercise, ET-1 levels were still significantly less in test 4
than in test 2 (5.1  0.3 vs. 9.5  1.6 pg/ml, p  0.01).
Finally, the increment in ET-1 levels at peak exercise was
positively correlated with the duration of ST-segment
depression during the recovery period (r  0.31, p  0.02).
Plasma NO2
/NO3 remained unchanged during all ex-
ercise (F  1.56, p  0.21), and the test effect was not
significant (F  0.08, p  0.97).
Two-way ANOVA with repeated measures showed
highly significant differences in lactate levels during the
exercise period for the four tests (F 49.4, p 0.0001). No
test effect was found (F  0.21, p  0.9), and no significant
interaction between the effect of changes in lactate levels
and different treatments was found (F  0.9, p  0.7).
During the first 10 min of infusion, blood lactate levels
remained unchanged in all tests, although they increased
during exercise, with a peak at peak exercise, and thereafter
declining in all tests.
DISCUSSION
The results of this study confirm our previous observation
(7) that, in patients with stable CAD, unfractionated
heparin may significantly decrease the ischemic threshold.
The administration of TMZ blunts the deleterious effects of
heparin, probably by inhibiting oxidative phosphorylation
Figure 2. Bar graphs pertaining to the magnitude of maximal ST-segment
depression (mm) and to the number of involved electrocardiographic leads
(mean values  SD for both), during saline and heparin, with placebo and
trimetazidine (TMZ). Solid bar  saline and placebo; striped bar 
heparin and placebo; checkered bar  heparin and TMZ; open bar 
saline and TMZ.
Figure 3. Bar graphs pertaining to the rate–pressure product (RPP) (mm
Hg  beats/min; mean value  SD) at 1-mm ST-segment depression and
at peak exercise, during saline and heparin, with placebo and trimetazidine
(TMZ). Solid bar  saline and placebo; striped bar  heparin and
placebo; checkered bar  heparin and TMZ; open bar  saline and
TMZ.
Figure 4. Diagram pertaining to free fatty acid (FFA), endothelin-1
(ET-1), nitric oxide (NO) and lactate levels (mean values  SE) 15 min
before exercise testing, at time 0, at peak exercise and 10, 15 and 20 min
after exercise testing, during saline and heparin, with placebo and trimeta-
zidine (TMZ). Solid circles  saline and placebo; striped squares 
heparin and placebo; checkered squares  heparin and TMZ; open
circles  saline and TMZ. *p  0.01 versus saline and placebo and versus
heparin and placebo. #p  0.01 versus time 0. ‡p  0.01 versus heparin
and placebo and versus heparin and TMZ. §p  0.05 versus heparin and
placebo.
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and FFA oxidation and by enhancing glucose metabolism
(16).
Effects of heparin on ischemic myocardium: role of
FFAs. A variety of mechanisms have been suggested to
explain the deleterious effects of fatty acids and their
derivatives on myocardial function during ischemia and
reperfusion (26). Indeed, in the ischemic myocardium,
long-chain fatty acids accumulate quickly. The rate of fatty
acid uptake and oxidation by the heart is controlled by the
availability of fatty acids (27). Exogenous fatty acids, the
main metabolic fuel of the myocardium under aerobic
conditions, are detrimental under oxygen deprivation, be-
cause their presence further augments the accumulation of
long-chain acyl esters in the myocytes. The accumulation of
lipids and their degradation may contribute to the progres-
sion of injury. Furthermore, during reperfusion, fatty acid
oxidation can quickly recover and become the dominant
source of ATP production. A high rate of fatty acid
oxidation contributes to a marked decrease in cardiac
efficiency during the ischemia-reperfusion period. There-
fore, an increase in fatty acid release induced by heparin and,
to a lesser extent, by its low-molecular-weight fragments
(8,9) may further worsen the local metabolic milieu, and
although the net effect of unfractionated heparin adminis-
tration remains beneficial, mainly because of its antithrom-
botic effect, it is not known yet whether the adverse effects
outlined in this study and previously (7) have any clinical
relevance in the setting of acute coronary syndromes. The
fact that the RPP at 1-mm ST-segment depression was
similar during all study phases indicates that the observed
decrease in the ischemic threshold after heparin was likely
caused by poor management of energetic resources, rather
than the result of alterations in the supply/demand ratio.
However, if glucose oxidation is stimulated during
ischemia-reperfusion, a significant increase in metabolic
efficiency ensues, which causes a parallel increase in cardiac
function and lesser injury. When translating these findings
into clinical practice, it appears that drugs acting as FFA
inhibitors may play a significant role in the treatment of
ischemic heart disease (28–31).
Manipulation of cardiac metabolism. A number of dif-
ferent approaches have been used to manipulate energy
metabolism in the heart (32). These involve both indirect
measures and the use of agents that act directly on the heart
to shift energy substrates utilization away from fatty acid
metabolism and toward glucose metabolism. One way to
increase glucose oxidation and to decrease fatty acid metab-
olism in the heart is to decrease circulating fatty acid levels.
This can be achieved by the administration of glucose/
insulin solutions (33), nicotinic acid (34) and beta-
adrenergic blocking agents (35,36). Another approach con-
sists of directly modifying substrate utilization by the heart.
Experimental studies with metabolic modulators suggest
that inhibition of oxidative phosphorylation and fatty acid
substrates can shift substrate utilization from fatty acid
oxidation to glucose (37–39). In our study, the beneficial
effects of TMZ were operative, regardless of the levels of
FFA which were not affected by TMZ. Rather than
reducing FFA blood levels, TMZ probably inhibited the
utilization of fatty acid substrates.
Effects of TMZ on cardiac metabolism. In isolated rat
hearts undergoing ischemia/reperfusion, TMZ delays the
occurrence of ischemic contracture and improves recovery of
post-ischemic left ventricular dysfunction (40), as well as
accelerates the recovery of mitochondrial oxidative phos-
phorylation and phosphocreatine resynthesis (41). Fantini et
al. (15) observed that the utilization of palmitoyl-carnitine
by isolated cardiac mitochondria is inhibited by high doses
of TMZ, in the absence of significant changes in pyruvate
and citrate oxidation. Additional studies also suggest that
TMZ acts by affecting myocardial substrate utilization,
because the drug inhibits oxidative phosphorylation and
utilization of fatty acid substrates and shifts metabolism
from fatty acid to glucose oxidation (42). Specifically, the
agent inhibits beta-oxidation by selectively blocking the
activity of 3-ketoacyl coenzyme A thiolase, the last enzyme
of the oxidative chain (16). The preferential oxidation of
glucose observed during TMZ infusion affords even greater
protection during reperfusion than during acute ischemia
(39). The reported reduction, by TMZ, of cellular acidosis
induced by ischemia (12) is probably secondary to the
improvement of mitochondrial function. All of these effects
may contribute to reduce the deleterious effects of the
ischemic insult, and, because they occur in the absence of
detectable changes in systemic and coronary hemodynamic
variables, the in vivo effects of TMZ on the ischemic
myocardium are likely to depend on direct cytoprotection.
Effects of heparin and TMZ on ET-1 release. In patients
with stable CAD, heparin may significantly decrease the
ischemic threshold, probably by increasing plasma concen-
trations of FFAs, which can adversely affect the metabolism
of the ischemic myocardium (7). The administration of
TMZ appears to completely abolish the deleterious effects
of the heparin-induced increase of FFAs, probably by
promoting the mitochondria’s utilization of glucose and
nonfatty substrates, allowing improvement of its ability to
sustain ischemia. Besides altering the metabolic balance of
the ischemic myocardium, increased FFA release may ad-
versely influence endothelial function (43). In our study, all
patients exhibited a marked increase in ET-1 during exer-
cise. However, ET-1 release significantly decreased with
exercise when patients were taking TMZ. This decrement
was greater during saline than during heparin. It has been
shown (44) that, in physiologic conditions, coronary endo-
thelial cells predominantly utilize exogenous glucose for
energy production. In these cells, glucose effectively sup-
presses the oxidation of lactate and palmitate, which are the
preferred substrates for the whole heart. Similar to the
cardiac muscle, both ischemia and an increased availability
of FFA may negatively affect the endothelial cells’ metabo-
lism and cause the release of endothelial factors. One
hypothesis is that improved myocardial and endothelial
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metabolism, together with the recent confirmation that
TMZ reduces intracellular acidosis during ischemia (45),
which could not only influence myocardial but also endo-
thelial membranes, may help to explain the reduction in
exercise-induced ET-1 release (and ischemia) observed with
TMZ.
A second hypothesis is that, by just decreasing the
severity of myocardial ischemia, TMZ can inhibit ET-1
release. Experimental data support the hypothesis that
myocardial ischemia, by itself, contributes to the release of
ET-1 in plasma (46,47). In fact, apart from endothelial cells
(48) and vascular smooth muscle cells (47), cardiomyocytes
(49) have also been shown to produce ET-1 in response to
myocardial ischemia. Furthermore, it has been shown very
recently that endothelin release is a marker of ischemic
severity rather than ischemia itself (50), and that TMZ, in
the presence of high triglycerides levels, may improve both
myocardial contractile recovery and ET-1 release after
low-flow ischemia (51). Therefore, the decrease in ET-1
release observed with TMZ could likely be linked to a
TMZ-induced reduction of myocardial ischemia, although,
conversely, the increase in ET-1 release after heparin could
be related to a greater magnitude of ischemia during this
arm of the study.
The hypotensive effects of endothelin-converting enzyme
inhibitors and endothelin receptor antagonists could be
useful in the treatment of different cardiovascular diseases.
Development of such agents will increase our knowledge of
the physiologic and pathologic roles of the endothelins and
should generate drugs with novel benefits. Whether TMZ
could also play a role in this setting has yet to be deter-
mined.
Effects of TMZ in ischemic heart disease. Trimetazidine
is an anti-anginal agent that increases cell tolerance to
ischemia. The beneficial effects of oral TMZ on the fre-
quency and severity of anginal attacks, as well as exercise
capacity, have been shown in several clinical studies (17–22).
The results of the present study confirm previous findings,
by showing that, compared with placebo, TMZ increased
the ischemic threshold when patients were receiving saline
(test 1 vs. test 4). Furthermore, this study shows that in the
experimental setting of increased FFA availability, as gen-
erated by unfractionated heparin, the addition of TMZ
partly reverses the negative metabolic effect of these metab-
olites. These findings are consistent with the notion that
TMZ, in addition to providing symptom relief and func-
tional improvement in patients with angina pectoris, also
has a cytoprotective action during ischemia.
Conclusions. In patients with stable CAD, heparin re-
duces the ischemic threshold. Trimetazidine appears to
reduce the effects of heparin, probably by inhibiting
oxidative phosphorylation and FFA oxidation and by
enhancing glucose metabolism. The concomitant novel
observation of reduced ET-1 release is likely to be also
dependent on TMZ-induced improvement of endothelial
metabolism. Both mechanisms are likely to contribute
significantly to the beneficial effect of TMZ. We believe
that our observations are important and potentially rele-
vant to the management of patients with a variety of
cardiovascular conditions.
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